AVROBIO, Inc. (NASDAQ:AVRO) Stock Position Decreased by Russell Investments Group Ltd.

Russell Investments Group Ltd. lessened its holdings in AVROBIO, Inc. (NASDAQ:AVRO) by 8.5% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 45,479 shares of the company’s stock after selling 4,244 shares during the quarter. Russell Investments Group Ltd.’s holdings in AVROBIO were worth $403,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of AVRO. Federated Hermes Inc. boosted its position in shares of AVROBIO by 82.0% in the first quarter. Federated Hermes Inc. now owns 2,280,771 shares of the company’s stock worth $28,943,000 after buying an additional 1,027,771 shares during the period. JPMorgan Chase & Co. boosted its position in shares of AVROBIO by 9.5% in the first quarter. JPMorgan Chase & Co. now owns 4,931,655 shares of the company’s stock worth $62,583,000 after buying an additional 425,910 shares during the period. Point72 Asset Management L.P. acquired a new stake in shares of AVROBIO in the first quarter worth $5,091,000. BlackRock Inc. boosted its position in shares of AVROBIO by 7.9% in the first quarter. BlackRock Inc. now owns 3,489,127 shares of the company’s stock worth $44,277,000 after buying an additional 254,049 shares during the period. Finally, Janus Henderson Group PLC boosted its position in shares of AVROBIO by 185.6% in the first quarter. Janus Henderson Group PLC now owns 320,993 shares of the company’s stock worth $4,069,000 after buying an additional 208,611 shares during the period. 74.08% of the stock is owned by institutional investors and hedge funds.

In other AVROBIO news, Director Philip J. Vickers acquired 4,800 shares of the company’s stock in a transaction dated Wednesday, July 7th. The shares were acquired at an average cost of $8.35 per share, for a total transaction of $40,080.00. Following the completion of the purchase, the director now owns 4,800 shares of the company’s stock, valued at approximately $40,080. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 6.40% of the company’s stock.

AVRO has been the subject of several recent research reports. Morgan Stanley cut their price objective on AVROBIO from $31.00 to $29.00 and set an “overweight” rating for the company in a report on Friday, July 16th. BTIG Research reiterated a “buy” rating and set a $23.00 price objective on shares of AVROBIO in a report on Friday, August 6th. Needham & Company LLC initiated coverage on AVROBIO in a report on Thursday, May 27th. They set a “buy” rating and a $28.00 price objective for the company. Finally, Zacks Investment Research upgraded AVROBIO from a “sell” rating to a “hold” rating in a report on Monday, September 6th. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $24.27.

NASDAQ AVRO opened at $6.25 on Friday. The stock’s 50-day moving average is $6.63 and its two-hundred day moving average is $8.98. The firm has a market cap of $272.63 million, a P/E ratio of -2.00 and a beta of 1.34. AVROBIO, Inc. has a fifty-two week low of $5.44 and a fifty-two week high of $20.07.

AVROBIO (NASDAQ:AVRO) last posted its quarterly earnings data on Wednesday, August 4th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.08). On average, analysts forecast that AVROBIO, Inc. will post -2.86 earnings per share for the current fiscal year.

AVROBIO Profile

Avrobio, Inc engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firm’s clinical-stage programs include Fabry, Gaucher Type 1, Hunter syndrome Gaucher Type 3, Pompe, and Cystinosis.

Recommended Story: After-Hours Trading

Want to see what other hedge funds are holding AVRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AVROBIO, Inc. (NASDAQ:AVRO).

Institutional Ownership by Quarter for AVROBIO (NASDAQ:AVRO)

Receive News & Ratings for AVROBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVROBIO and related companies with MarketBeat.com's FREE daily email newsletter.